[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy":33},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,81,0,25,[9,56,88,118,146,174,194,220,256,278,308,336,360,384,400,415,440,463,487,506,531,556,580,607,643],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":40,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":4},"100054125","quality-of-life-of-patients-who-have-undergone-bilateral-mastectomy-100054125",false,"NCT07699913","Quality of Life of Patients Who Have Undergone Bilateral Mastectomy","Psychological Experience, Quality of Life, and Patient Satisfaction Following Bilateral Breast Reconstruction After Prophylactic or Therapeutic Mastectomy, Using the BREAST-Q Questionnaire.","RM BREAST Q","Inclusion Criteria:\n\n* Female sex\n* Age ≥ 18 years\n* Bilateral mastectomy\n* Breast reconstruction between January 1, 2015, and January 1, 2026\n* No objection to the study\n\nExclusion Criteria:\n\n* Individual under guardianship or curatorship, or deprived of liberty\n* Reconstruction not completed by January 1, 2026.","FEMALE","18 Years",{"count":21,"type":22},115,"ESTIMATED","OBSERVATIONAL","We therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast reconstruction, influence the quality of life and satisfaction of patients who have undergone bilateral mastectomy. The goal of this observational study is thus to measure and compare the quality of life of patients who have undergone bilateral mastectomy using the BREAST-Q questionnaire.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Surgery Date","Age","BMI","Height","Weight","Smoking Status","Hormone Therapy","Chemotherapy","Radiotherapy","Postoperative Complications","Type of Reconstruction (Flap or Implant)","Timing of Reconstruction","Type of Mastectomy (Prophylactic or Therapeutic)","BRCA Mutation",[41,42,43],"Comparative","observational","retrospective","NOT_YET_RECRUITING","2026-07-07",{"date":47,"type":48},"2026-07-13","ACTUAL",{"date":50,"type":22},"2026-07-10",{"date":52,"type":22},"2026-08-20",{"name":54,"class":55},"University Hospital, Grenoble","OTHER",{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":63,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100606424","resilience-enhancement-using-electronic-frailty-index-directed-care-pathway-100606424","NCT07175376","Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway","Resilience Enhancement Utilizing an Electronic Frailty Index-Directed Care Pathway for Older Adults Receiving Chemotherapy (RESILIENCE-e): A Prospective Single-Arm Interventional Study","Inclusion Criteria:\n\nPatients with cancer:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent\n* Age ≥ 65 years at the time of enrollment.\n* Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic\u002Fimmune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.\n* eFI pre-frail or frail status (available in EHR; defined as eFI \\> 0.10) within 30 days before enrollment.\n* Ability to read and understand the English language\n\nProviders:\n\n* Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment.\n\nExclusion Criteria:\n\nPatients:\n\n* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.\n* Chemotherapy planned at a facility outside the Atrium Health system.\n* Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).","ALL","65 Years",{"count":66,"type":22},32,"INTERVENTIONAL",[69],"NA","The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.",[72,73,33],"Cancer","Frail",[72,75,76],"Frailty Index","eFI score","RECRUITING","2026-07-01",{"date":80,"type":48},"2026-07-02",{"date":82,"type":48},"2026-03-16",{"date":84,"type":22},"2027-05",{"name":86,"class":55},"Wake Forest University Health Sciences",2,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":67,"phases":98,"briefSummary":99,"conditions":100,"keywords":107,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100645034","effect-of-virtual-reality-guided-imagery-on-pain-anxiety-and-fatigue-in-cancer-patients-undergoing-chemotherapy-100645034","NCT07677436","Effect of Virtual Reality-Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy","Effect of Virtual Reality Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial","VRGI-Chemo Tri","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histologically confirmed breast cancer.\n* Stage I, II, or III breast cancer.\n* Underwent surgery as the initial treatment and are scheduled to receive the first cycle of adjuvant chemotherapy, with or without biologic therapy (e.g., AC or TC regimens).\n* Able to read, write, and communicate.\n* Able and willing to use a virtual reality headset.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Visual or hearing impairment that prevents the use of virtual reality.\n* Serious neurological or psychiatric disorders.\n* Current participation in other non-pharmacological interventions (e.g., meditation or relaxation therapy) that could influence the study outcomes.\n* Previous experience with virtual reality-guided imagery.\n* Use of analgesics, anxiolytics, or other medications during the intervention that may affect the study outcomes.",{"count":97,"type":22},108,[69],"This randomized controlled trial aims to evaluate the effectiveness of virtual reality-guided imagery in reducing pain, anxiety, and fatigue among female breast cancer patients undergoing adjuvant chemotherapy. Participants will be randomly assigned to either an intervention group receiving virtual reality-guided imagery in addition to routine care, or a control group receiving routine care",[101,102,103,33,104,105,106],"Virtual Reality","Guided Imagery","Breast Cancer","Pain","Anxiety","Fatigue",[108],"Virtual Reality, Guided Imagery , Breast Cancer, Chemotherapy , Pain, Anxiety , Fatigue","2026-06-27",{"date":111,"type":48},"2026-06-30",{"date":78,"type":22},{"date":114,"type":22},"2027-03",{"name":116,"class":55},"Thoalfokar Mohammed Al-Obaidi",1,{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":67,"phases":127,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":117},"100644315","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-early-stage-cancer-100644315","NCT07663396","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of early-stage cancer(I-III stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. Non small cell lung cancer or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal; Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with advanced cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":126,"type":22},278,[69],"This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with early stage cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[130,33,131,132],"Electroacupuncture","Peripheral Neuropathy","Early Stage Cancer",[134,33,135,136],"electroacupuncture","Peripheral neuropathy","early stage cancer","2026-06-17",{"date":139,"type":48},"2026-06-23",{"date":141,"type":22},"2026-05-25",{"date":143,"type":22},"2029-07-31",{"name":145,"class":55},"Affiliated Hospital of Qinghai University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":67,"phases":157,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":117},"100619043","phase-2-intestinal-low-dose-radiotherapy-plus-immunochemotherapy-for-conversion-of-borderline-resectableunresectable-esophageal-squamous-cell-carcinoma-100619043","NCT07339488","Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy Plus Tislelizumab and Chemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","ILDR-03","Inclusion Criteria:\n\n1. Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance.\n2. Age ≥18 years and ≤75 years; both sexes are eligible.\n3. ECOG performance status score of 0-1.\n4. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.\n5. Thoracic esophageal cancer.\n6. Unresectable lesions, defined as: T4 stage; marginally resectable T3 stage (invading other organs, e.g., trachea, bronchus, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence of supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.\n7. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.\n8. Baseline laboratory requirements (within 7 days prior to enrollment):\n\n   Hematology:\n   1. Hb≥90 g\u002FL (no transfusion within 14 days)\n   2. NEUT ≥1.5×10⁹\u002FL\n   3. PLT ≥100×10⁹\u002FL\n   4. WBC≥3×10⁹\u002FL\n\n   Biochemistry:\n   1. ALT and AST≤2.5×ULN\n   2. TBIL≤1.5×ULN\n   3. SCr≤1.5×ULN; or CrCl≥60 mL\u002Fmin Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3\u002FFT4 levels should also be considered; eligible if FT3\u002FFT4 are normal) Echocardiography: LVEF≥50%\n9. Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.\n10. No psychological, familial, social, or geographical factors that may impair protocol adherence.\n11. Other parameters meet general clinical trial enrollment criteria.\n12. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases other than supraclavicular lymph node metastases.\n2. Presence or high risk of esophageal perforation.\n3. Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy.\n4. Patients who previously experienced unacceptable toxicity after receiving ICI therapy.\n5. Patients with a history of thoracoabdominal\u002Fpelvic radiotherapy within 6 months prior to enrollment.\n6. Adverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).\n7. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.\n8. Respiratory depression, airway obstruction, or tissue hypoxia.\n9. Severe cardiac disease (i.e., NYHA functional class II or higher).\n10. Markedly abnormal liver or kidney function (i.e., indicators \\>3 times the upper limit of normal).\n11. Active hepatitis B, hepatitis C, HIV, or syphilis.\n12. Active brain disease or central nervous system\u002Fmeningeal metastases with significant symptoms, or impaired decision-making capacity.\n13. Hypersensitivity to drugs included in the trial.\n14. Drug and\u002For alcohol abuse.\n15. Pregnant or lactating women.\n16. Concurrent participation in another therapeutic clinical trial.\n17. Major surgical procedure within 30 days prior to enrollment.\n18. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.","75 Years",{"count":156,"type":22},43,[158],"PHASE2","Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life compared to those who do not receive surgical intervention.\n\nCurrent conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy.\n\nRetrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles.\n\nBased on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR\u002FUR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 43 cases in two seperated stages, focusing on patients with thoracic BR\u002FUR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg\u002Fm² on day 1), cisplatin (75 mg\u002Fm² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.",[161,162,163,164,33,34,165],"Borderline Resectable Carcinoma","Unresectable Cancer","Esophageal Squamous Cell Carcinoma (ESCC)","Immune Checkpoint Inhibitor","Tislelizumab",{"date":167,"type":48},"2026-06-18",{"date":169,"type":48},"2025-12-05",{"date":171,"type":22},"2028-11-01",{"name":173,"class":55},"Chuangzhen Chen",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":67,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":192,"leadSponsor":193,"locationsCount":117},"100642496","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-advanced-cancer-100642496","NCT07644533","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of advanced cancer(IV stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer;\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. NSCLC or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with early-stage cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":182,"type":22},264,[69],"This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with advanced cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[130,33,186,131],"Advanced Cancer",[33,186,135,130],"2026-06-10",{"date":190,"type":48},"2026-06-12",{"date":141,"type":22},{"date":143,"type":22},{"name":145,"class":55},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":67,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100430810","alnd-vs-art-in-positive-sentinel-node-after-neoadjuvant-therapy-in-breast-cancer-100430810","NCT04889924","ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer","Axillary Lymph Node Dissection Versus Axillary Radiotherapy in Breast Cancer Patients With Positive Sentinel Node After Neoadjuvant Therapy: A Multicenter Randomized Study","ADARNAT","Inclusion Criteria:\n\n* T1-T4 N0\u002F T0-T4 N1 at diagnosis and subsidiary of neoadjuvant treatment\n* Post-CT SLN with ≤2 macrometastasis\u002Fmicrometastasis or ITCs\n* Post-CT axillary response by ultrasound or MRI\n* Complete at least 70% of neoadjuvant chemotherapy and 6 months of endocrine treatment.\n\nExclusion Criteria:\n\n* cN2\n* ypN0\n* History of breast surgery for ipsilateral cancer in the last 10 years\n* History of other cancer in the last 5 years, except squamous carcinoma of the skin.",{"count":203,"type":22},820,[69],"In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis and does significantly reduce the appearance of lymphedema. However, patients who have received neoadjuvant systemic treatment cannot benefit from this option, even though in the majority of those who have responded well to treatment, a residual disease in the armpit is low, but there are no studies yet published that supports the possibility of not performing lymphadenectomy.\n\nThe primary endpoint is to evaluate wether axillary radiotherapy (ART) presents a lower risk of lymphedema with respect to lymphadenectomy (ALND) in patients with breast cancer who, after neoadjuvant systemic treatment (NST), present the sentinel node affected. Likewise, we will evaluate recurrences and overall survival in both groups. Finally, we will analyze the quality of life of these patients.",[103,33,207,208,209],"Sentinel Lymph Node","Axillary Lymph Nodes Dissection","Radiotherapy Side Effect","2026-05-18",{"date":212,"type":48},"2026-05-19",{"date":214,"type":48},"2021-06-11",{"date":216,"type":22},"2028-12-31",{"name":218,"class":55},"Hospital Universitari de Bellvitge",60,{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":67,"phases":229,"briefSummary":231,"conditions":232,"keywords":241,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":117},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":228,"type":22},400,[158,230],"PHASE3","This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[233,234,235,34,33,236,209,237,238,239,240],"Rectal Cancer","Total Neoadjuvant Treatment","Neoadjuvant Therapy","Organ Preservation","Chemotherapy Side Effects","Chemoradiotherapy","Low Anterior Resection Syndrome","Quality of Life",[242,234,243,34,33,238,236,209,244,245,106,246,239],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Postoperative complications","2026-05-06",{"date":249,"type":48},"2026-05-11",{"date":251,"type":48},"2025-01-06",{"date":253,"type":22},"2029-12-27",{"name":255,"class":55},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":67,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":277},"100511615","phase-3-ic-plus-low-dose-radiation-plus-cadonilimab-in-lanpc-100511615","NCT05941741","IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","Induction Chemotherapy Combined With Low-dose Radiation Plus Cadonilimab in Loco-regionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Open-label, Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage T4N1M0 and T1-4N2-3M0 (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy, radiotherapy or immunotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 9g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Distant metastases;\n* Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Pregnancy or lactation;\n* Have uncontrolled cardiovascular disease;\n* Severe complication, eg, uncontrolled hypertension;\n* Mental disorder;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts.","70 Years",{"count":265,"type":22},380,[230],"This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.",[269,164,34,33],"Nasopharyngeal Carcinoma",{"date":249,"type":48},{"date":272,"type":48},"2024-01-10",{"date":274,"type":22},"2029-12",{"name":276,"class":55},"Sun Yat-sen University",3,{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":67,"phases":287,"briefSummary":288,"conditions":289,"keywords":293,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":117},"100636937","phase-2-sotagliflozin-as-prevention-of-anthracycline-related-cardiotoxicity-100636937","NCT07572175","Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity","SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)","SPARTACUS","Inclusion Criteria\n\n* Patients ≥ 18 years\n* Newly diagnosed lymphoma\n* Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg\u002Fm2)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n\nExclusion Criteria\n\n* Prior anthracycline treatment\n* Previous malignancy requiring any chemotherapy or radiotherapy\n* Previous treatment with SGLT2i (eg due to T2DM) or SGLT1\u002F2i\n* Previous heart failure (HF patients should already be on SGLT2i as per guidelines)\n* LVEF\\\u003C40% (even in the absence of HF):\n* Pregnancy or breastfeeding\n* Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)",{"count":219,"type":22},[158],"This project aims to determine the benefits of the dual SGLT1\u002F2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.",[290,291,33,292],"Anthracycline-induced Cardiotoxicity","Lymphoma","Cardiotoxicity",[294,295,296,297,298],"anthracycline","left ventricular dysfunction","cardiotoxicity","SGLT inhibitors","prevention","2026-04-30",{"date":301,"type":48},"2026-05-07",{"date":303,"type":22},"2026-07",{"date":305,"type":22},"2029-10",{"name":307,"class":55},"Icahn School of Medicine at Mount Sinai",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":317,"conditions":318,"keywords":323,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":117},"100627052","measuring-fluid-buildup-in-cancer-patients-100627052","NCT07443618","Measuring Fluid Buildup in Cancer Patients","Monitoring of Oedema in Cancer Patients - A Pilot Study","Inclusion Criteria (Outpatient breast cancer patients with lymphoedema after radiotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving radiotherapy due to breast cancer within the last 6 months\n* Is being followed in the Oncology Outpatient Clinic at Aalborg University Hospital\n* Age ≥ 18 years\n* Visible lymphoedema in at least one upper extremity\n\nInclusion Criteria (Hospitalized cancer patients with peripheral oedema in one or both lower extremities after chemotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving chemotherapy due to cancer within the last 2 months\n* Hospitalised in the Oncology Ward at Aalborg University Hospital\n* Estimated length of hospital stay of at least 6 days\n* Age ≥ 18 years\n* Visible peripheral oedema in at least one lower extremity\n\nExclusion Criteria (both groups):\n\n* Pregnant or breastfeeding women\n* Amputated limb(s)\n* Pacemaker or implanted cardioverter-defibrillator due to risk of interference from the electrical signal\n* Metallic prostheses due to risk of interference with the device signal\n* Inability to lie still for the duration of the measurement interval (minimum 2 minutes at a time)\n* Inability to stand on a scale, i.e. permanently bedridden.\n* Inability to cooperate with urine collection\n* Receiving dialysis\n* Terminal illness",{"count":316,"type":22},46,"The goal of this study is to improve the monitoring of fluid retention in cancer patients. The main question it aims to answer is: Can segmental bioelectrical impedance analysis be used to monitor local fluid retention (edema) in cancer patients? We will include:\n\n* Breast cancer patients with fluid and or lymph retention in one or both arms after radiotherapy (outpatients)\n* Cancer patients with fluid retention in one or both legs after chemotherapy (hospitalized)\n\nParticipants will:\n\n* Have measurements taken using bioelectrical impedance\n* Provide blood samples and 24-hour urine collection\n* Weight monitorering\n* Complete diet and fluid registration (inclusive enteral and parenteral)\n* Have clinical palpatory and measurement assessment of oedema.",[72,319,320,321,33,34,322],"Oedema","Bioelectrical Impedance","Lymphoedema","Fluid Balance",[324,325,326],"Localized oedema in cancer","Bioelectrical impedance","Post radiation lymphoedema","2026-04-28",{"date":329,"type":48},"2026-04-29",{"date":331,"type":48},"2026-02-01",{"date":333,"type":22},"2026-07-31",{"name":335,"class":55},"Jens Rikardt Andersen",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":63,"minAge":4,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":67,"phases":345,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100619596","phase-2-comparing-of-sesame-oil-nitroglycerin-ointment-and-aloe-vera-gel-100619596","NCT07346677","Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel","Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel on Prevention of Phlebitis Induced by Chemotherapy","Inclusion Criteria:\n\n* adult conscious patients of both gender.\n* Patients receiving chemotherapy antimetabolites (5-fluorouracil).\n* Patients receiving chemotherapy alkylating agents (Cisplatin).\n* Patients receiving chemotherapy through peripheral IV cannula.\n* Patients breast cancer colon cancer.\n\nExclusion Criteria:\n\n* Phlebitis has already appeared at the IV infusion site.\n* Patients using port or central venous catheters to administer chemotherapy. - Patient radiation therapy, immunity therapy and palliative therapy\n* Patients receiving chemotherapy (antitumor antibiotics, plant alkaloids).",{"count":344,"type":22},190,[158],"compare the effectiveness sesame oil, aloe Vera gel, and nitroglycerin ointment prevention of phlebitis.",[72,33],[349,350,351,352],"sesame oil","aloe Vera gel","nitroglycerin ointment","phlebitis","2026-04-27",{"date":327,"type":48},{"date":249,"type":22},{"date":357,"type":22},"2026-07-20",{"name":359,"class":55},"University of Basrah",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":67,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":117},"100636193","phase-2-randomized-trial-of-plasma-ctdna-methylation-guided-adjuvant-therapy-in-t4n0-and-low-risk-stage-iii-colorectal-cancer-100636193","NCT07562503","Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","CLEAR-03","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of sex;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of \\>3 months;\n3. Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;\n4. Positive ctDNA status at 1 month after surgery;\n5. Expected survival of \\>12 months;\n6. Ability to understand and willingness to sign a written informed consent form (personally or via a legally authorized representative\u002Fguardian), indicating that the subject understands the study objectives and required procedures and agrees to participate.\n\nExclusion Criteria:\n\n1. Receipt of neoadjuvant therapy prior to surgery;\n2. Blood transfusion during surgery or within 2 weeks prior to surgery;\n3. Pregnant or breastfeeding women, or individuals of reproductive potential who are not using adequate contraception;\n4. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer;\n5. Uncontrolled primary brain tumors or central nervous system metastases, or presence of significant intracranial hypertension or neuropsychiatric symptoms;\n6. Presence of severe or uncontrolled comorbidities, including but not limited to:Severe cardiac disease that remains unstable despite treatment, including myocardial infarction, congestive heart failure, unstable angina, symptomatic pericardial effusion, or unstable arrhythmia within 6 months prior to enrollment; Clearly diagnosed neurological or psychiatric disorders, including dementia or seizure disorders;Severe or uncontrolled infections;Active disseminated intravascular coagulation (DIC) or significant bleeding tendency;Significant impairment of major organ function;\n7. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.","80 Years",{"count":369,"type":22},340,[158],"The patient (T4N0 or low-risk stage III) will be randomly assigned to either the control group (FOLFOX\u002FCAPOX for 3 months) or the intervention group (FOLFOX\u002FCAPOX for 6 months or FOLFOX\u002FCAPOX for 3 months followed by FOLFIRI\u002FCAPIRI for 3 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months after surgery for dynamic monitoring of plasma ctDNA.",[373,374,33],"ctDNA","Colorectal Cancer","2026-04-26",{"date":377,"type":48},"2026-05-01",{"date":379,"type":48},"2024-11-01",{"date":381,"type":22},"2027-12-31",{"name":383,"class":55},"Fudan University",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":367,"enrollmentInfo":390,"targetDuration":4,"studyType":67,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":117},"100636192","phase-2-a-randomized-controlled-trial-of-plasma-ctdna-methylation-guided-adjuvant-chemotherapy-decision-making-in-high-risk-stage-iii-t4n-or-t1-3n2-colorectal-cancer-100636192","NCT07562490","A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer","CLEAR-04",{"count":391,"type":22},100,[158],"Patients with T4N+ or T1-3N2 disease will be randomly assigned to either the control group (FOLFOX\u002FCAPOX for 6 months) or the intervention group (FOLFOX\u002FCAPOX plus bevacizumab for 6 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months postoperatively for dynamic monitoring of plasma ctDNA.",[373,33,374],{"date":377,"type":48},{"date":397,"type":48},"2025-04-01",{"date":381,"type":22},{"name":383,"class":55},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":405,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":367,"enrollmentInfo":406,"targetDuration":4,"studyType":67,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":413,"leadSponsor":414,"locationsCount":117},"100636209","phase-2-randomized-study-of-plasma-ctdna-methylation-to-guide-adjuvant-chemotherapy-decisions-in-high-risk-t3n0-colorectal-cancer-100636209","NCT07562711","Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","CLEAR-02",{"count":369,"type":22},[158],"This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery. It aims to investigate the impact of different adjuvant chemotherapy regimens on ctDNA clearance rates and their prognostic significance. By using postoperative ctDNA status to identify patients at high risk of recurrence, the study seeks to implement intensified chemotherapy strategies (treatment escalation) at an early stage, thereby improving ctDNA clearance and ultimately enhancing patient outcomes",[373,33,374],"2026-04-25",{"date":377,"type":48},{"date":379,"type":48},{"date":381,"type":22},{"name":383,"class":55},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":367,"enrollmentInfo":423,"targetDuration":4,"studyType":67,"phases":425,"briefSummary":426,"conditions":427,"keywords":431,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":437,"leadSponsor":438,"locationsCount":117},"100636153","phase-2-tislelizumab-plus-chemotherapy-and-bace-for-unresectable-nsclc-100636153","NCT07561983","Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC","Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)","BEACON-Lung","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n* Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system\n* Initially unresectable disease as determined by multidisciplinary team (MDT) assessment\n* At least 1 measurable intrapulmonary lesion according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Forced expiratory volume in the first second (FEV1) \\> 1.0 L and \\> 40% of predicted normal value\n* Estimated life expectancy of at least 3 months\n* Adequate organ function\n* Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment\n* Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Ability to understand and willingness to sign a written informed consent form\n\nExclusion Criteria:\n\n* Prior local therapy for NSCLC, including radiotherapy or interventional therapy\n* Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations\n* Distant organ metastasis\n* History of another malignancy within the past 5 years\n* Active autoimmune disease or history of autoimmune disease requiring systemic treatment\n* Known allergy to any study drug or excipient\n* Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment\n* Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis\n* Major surgery requiring general anesthesia within 4 weeks before first dose\n* Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk\n* Participation in another interventional therapeutic clinical study\n* Psychiatric illness or history of psychotropic drug abuse that may compromise study participation\n* Any condition judged by the investigator to make the patient unsuitable for the study",{"count":424,"type":22},39,[158],"The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:\n\n* What is the 1-year event-free survival (EFS) rate with this treatment?\n* Can this treatment improve tumor response and the chance of curative-intent resection?\n* What adverse events occur during treatment?\n\nParticipants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.",[428,165,33,429,430],"Unresectable Stage III Non-small Cell Lung Cancer","Chemoembolization, Therapeutic","Conversion Therapy",[432,165,33,433,430],"Unresectable Non-Small Cell Lung Cancer","Bronchial Artery Chemoembolization","2026-04-24",{"date":377,"type":48},{"date":377,"type":22},{"date":216,"type":22},{"name":439,"class":55},"Sichuan Cancer Hospital and Research Institute",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":449,"conditions":450,"keywords":453,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":117},"100635499","chemotherapy-induced-hearing-loss-and-health-inequality-100635499","NCT07553481","Chemotherapy-Induced Hearing Loss and Health Inequality","CANHEAR","Inclusion Criteria:\n\n* Patients receiving platinum-based chemotherapy drugs\n* Living and treated within North West England\n* Able to complete an online hearing and cognitive test\n* Fluent in English\n\nExclusion Criteria:\n\n* Following cancer types: brain tumour\u002Fmetastasis, head + neck, skin cancers around the ear, and adenoid cystic carcinoma of the auditory cortex\n* World Health Organisation performance status score of 3 or more\n* Stage 4 cancer\n* History of childhood deafness\n* Current or recent ear infections\n* Cochlear implant user\n* Known neurological impairment (e.g., stroke, traumatic brain injury, dementia)\n* Patients who look capacity to consent or complete study tasks",{"count":448,"type":22},172,"This project aims to understand how platinum-based chemotherapy affects hearing function in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based chemotherapy drugs, such as cisplatin, are ototoxic, meaning that they cause permanent damage to the hair cells of the ear, resulting in hearing loss. Patients from more deprived backgrounds face additional risk factors to their hearing health, including limited healthcare access, greater occupational noise exposure, and poorer overall health, making them more vulnerable to hearing loss.\n\nThis is especially concerning as hearing loss can make communication more challenging, which creates a greater reliance on cognitive processes such as thinking and memory to navigate social interactions. This challenge is exacerbated when individuals experience cognitive dysfunction related to chemotherapy, commonly referred to as 'chemo brain'. Addressing these communication difficulties is crucial for promoting healthy ageing and maintaining social engagement. It is expected that cancer patients from the most deprived backgrounds would experience greater hearing loss following chemotherapy than those from less deprived backgrounds.\n\nAs a secondary aim, this study will also investigate how hearing loss may affect cognitive function. Specifically, it will assess whether differences in speech-in-noise performance from pre- to post-treatment predict cognitive performance post-treatment, to understand if changes in hearing over time are associated with changes in cognition. The study will also explore how socioeconomic deprivation, cumulative chemotherapy dose, and treatment duration influence these relationships. By identifying disparities in hearing loss and possible associations with cognition, this research will help guide future hearing screening and intervention strategies for cancer patients.",[72,451,33,452],"Chemo Brain","Hearing",[72,454,33,452],"Chemo brain","2026-04-20",{"date":327,"type":48},{"date":458,"type":22},"2026-05-02",{"date":460,"type":22},"2028-09-01",{"name":462,"class":55},"Lancaster University",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":483,"leadSponsor":485,"locationsCount":117},"100634227","individualized-care-perceptions-of-patients-receiving-outpatient-chemotherapy-a-qualitative-study-100634227","NCT07536945","Individualized Care Perceptions of Patients Receiving Outpatient Chemotherapy: A Qualitative Study","Inclusion Criteria:\n\n* Continuing treatment at the Outpatient Chemotherapy Unit of the relevant hospital.\n* Voluntarily agreeing to participate in the study.\n* Being over 18 years of age.\n* Being proficient in Turkish.\n* Exclusion Criteria:\n* Not receiving ongoing treatment at the Outpatient Chemotherapy Unit of the relevant hospital.\n* Declining to participate in the study voluntarily.\n* Unwillingness to answer questions or lack of cooperation during the interview.",{"count":470,"type":22},10,"The purpose of this observational study is to learn how people receiving chemotherapy in a clinic without staying overnight (outpatient) feel about the care they receive. The study focuses on individualized care, which means nursing care that is tailored specifically to each person's unique needs, values, and lifestyle.\n\nBackground:\n\nCancer treatment often involves chemotherapy (medicine used to kill cancer cells). While these treatments help fight the disease, they can also cause side effects like nausea or tiredness, which affect daily life. Nurses play a key role in helping people manage these effects. This research aims to understand how \"individualized care\" helps participants feel valued and supported during their treatment journey.\n\nThe study aims to answer these key questions:\n\nHow do participants describe their experiences with nursing care?\n\nWhat are the specific needs and expectations of these individuals for care that feels personal to them?\n\nHow does personalized care affect their ability to manage symptoms and follow their treatment plan?\n\nScope and Setting:\n\nThis study will take place at the Yalova Training and Research Hospital within the Outpatient Chemotherapy Unit. The research will be conducted between May 1, 2026, and April 1, 2027.\n\nMethod and Participants:\n\nThe researchers plan to interview 10 to 20 participants who are over 18 years old and receiving treatment at the clinic. The final number of participants will be decided when the researchers find that no new information or themes are being discovered in the interviews (a stage called \"data saturation\").\n\nParticipants will:\n\nTake part in a private, one-on-one interview with a researcher.\n\nAnswer open-ended questions about their thoughts and feelings regarding their nursing care.\n\nAllow the interview to be voice-recorded to ensure all information is captured accurately.\n\nSpend approximately 30 to 45 minutes sharing their personal experiences.\n\nPrivacy and Ethics:\n\nParticipant privacy is a top priority. All personal information and voice recordings will be kept strictly confidential. In the final report, fake names (aliases) will be used so that no one can be identified. Participants can choose to leave the study at any time. The study follows international ethical rules to protect the rights of every participant.",[473,474,33],"Cancer Patients","Care",[476,477,478,479],"Individualized Care","Outpatient Chemotherapy","Patient Perception","Nursing Care",{"date":481,"type":48},"2026-04-23",{"date":377,"type":22},{"date":484,"type":22},"2027-04-01",{"name":486,"class":55},"University of Yalova",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":154,"enrollmentInfo":494,"targetDuration":4,"studyType":67,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":117},"100611352","phase-2-a-pilot-study-evaluating--hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-100611352","NCT07239466","A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer","A Single-Arm, Single-Center Study of Exploring the β-hydroxybutyrate Supplementation and Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n1. Patients or their family members agree to participate in the study and sign the informed consent form;\n2. Age 18-75 years, male or female;\n3. Histologically confirmed Locally Advanced rectal adenocarcinoma;\n4. inferior margin ≤ 10 cm from the anal verge;\n5. ECOG performance status score is 0-1;\n6. Untreated with anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery, etc;\n7. There was no operative contraindication;\n8. Laboratory tests were required to meet the following requirements: white blood cell (WBC) ≥ 4×109\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL; Platelet count ≥ 100×109\u002FL; Hemoglobin ≥90 g\u002FL; Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN); Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance rate ≥50 mL\u002Fmin; International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;\n9. Urinary protein \\\u003C 2+ or 24-hour urinary protein excretion \\\u003C 1 g at baseline.\n\nExclusion Criteria:\n\n1. Patients with non-pMMR LARC；\n2. Subjects who have previously received any form of immunotherapy, including but not limited to immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or any other treatment targeting tumor immunomodulatory mechanisms;\n3. Presence of any concurrent disease, condition (including laboratory abnormality), history of substance abuse, or current evidence thereof, which, in the judgment of the Investigator, may compromise subject safety, interfere with the process of obtaining informed consent, affect subject compliance, or confound the safety assessment of the investigational product(s).",{"count":7,"type":22},[158],"This study is a prospective phase II clinical trial aimed at exploring the potential benefits of supplementing β-hydroxybutyrate with existing short course radiotherapy sequential immunotherapy and CAPEOX therapy.",[233,34,498,33],"Immunotherapy",{"date":481,"type":48},{"date":501,"type":48},"2026-01-01",{"date":503,"type":22},"2027-06-01",{"name":505,"class":55},"Tao Zhang",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":517,"conditions":518,"keywords":519,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":527,"leadSponsor":529,"locationsCount":117},"100631529","investigation-of-digital-media-use-in-patients-receiving-chemotherapy-100631529","NCT07501871","Investigation of Digital Media Use in Patients Receiving Chemotherapy","Assessment of Digital Meda Use and eHealth Literacy in Patients Receiving Chemotherapy","DMU-CH","Inclusion Criteria:\n\n* Patients aged between 18 and 67 years\n* Receiving chemotherapy treatment\n* Able to communicate and understand the study procedures\n* Voluntarily agree to participate in the study\n\nExclusion Criteria:\n\n* Patients with cognitive impairment or communication difficulties\n* Patients who refuse to participate\n* Patients with incomplete questionnaire responses","67 Years",{"count":516,"type":22},80,"This study aims to examine digital media use and eHealth literacy among patients receiving chemotherapy. Digital media has become an important tool for accessing health information, communicating with healthcare providers, and supporting self-management.\n\nThis observational study will be conducted with adult patients receiving chemotherapy in an outpatient setting. Data will be collected using a sociodemographic information form and the eHealth Literacy Scale (eHEALS). The findings are expected to contribute to a better understanding of digital media use and digital health literacy levels in chemotherapy patients.",[72,33],[520,521,522],"Oncology Nursing","Digital Media","eHealth Literacy","2026-04-16",{"date":525,"type":48},"2026-04-21",{"date":455,"type":22},{"date":528,"type":22},"2026-05-20",{"name":530,"class":55},"Fenerbahce University",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":67,"phases":540,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":117},"100633845","phase-2-prospective-open-label-multi-cohort-study-of-becotatug-vedotin-with-tislelizumab-and-chemotherapy-in-esophageal-squamous-cell-carcinoma---phase-2-100633845","NCT07531979","Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2","A Prospective, Open-label, Multicohort, Phase II Clinical Study of Becotatug Vedotin in Combination With Tislelizumab and Chemotherapy for Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Male or non-pregnant, non-lactating female.\n3. ECOG performance status of 0 or 1, with no deterioration within 7 days.\n4. Histologically confirmed locally advanced or metastatic esophageal squamous cell carcinoma.\n5. No prior systemic therapy for ESCC. Patients who have received neoadjuvant or adjuvant therapy must have experienced disease progression or recurrence more than 6 months after completion of that treatment.\n6. Patients with metastatic disease must have at least one measurable lesion per RECIST 1.1 criteria; patients with disease after neoadjuvant therapy must have an evaluable lesion.\n7. Adequate organ and bone marrow function, as demonstrated by the following laboratory values:\n\n   1. Hemoglobin (HGB) ≥ 90 g\u002FL.\n   2. Absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹\u002FL.\n   3. Platelet count (PLT) ≥ 80 × 10⁹\u002FL.\n   4. Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN).\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN.\n   6. Creatinine clearance ≥ 50 mL\u002Fmin (calculated by the Cockcroft-Gault formula).\n   7. Urine protein \\\u003C (++) or 24-hour urinary protein \\\u003C 1.0 g.\n8. Normal coagulation function and no active bleeding:\n\n   1. International Normalized Ratio (INR) ≤ 1.5.\n   2. Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.\n9. For women of childbearing potential: negative pregnancy test (serum or urine) within 14 days prior to enrollment, and agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug. For men: surgically sterile or agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug.\n10. Expected survival ≥ 6 months.\n11. Patient voluntarily participates in the study and signs the informed consent form (ICF).\n12. Patient is expected to be compliant and able to undergo follow-up for efficacy and adverse events as required by the protocol.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria at screening will be excluded from the study:\n\n1. Prior treatment with any anti-EGFR monoclonal antibody, or with anti-PD-1\u002FPD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, CTLA-4 antibody, or any other drug\u002Fantibody targeting T-cell co-stimulation or checkpoint pathways.\n2. Administration of a live vaccine within 4 weeks prior to enrollment or anticipated during the study period.\n3. Active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment.\n4. Prior allogeneic bone marrow transplantation or solid organ transplant.\n5. Uncontrolled hypertension at enrollment, defined as: systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg.\n6. Any disease or condition affecting drug absorption at enrollment.\n7. Clinically significant cardiovascular disease, including but not limited to: acute myocardial infarction within 6 months prior to enrollment; severe\u002Funstable angina or coronary artery bypass grafting; congestive heart failure \\> New York Heart Association (NYHA) Class 2; ventricular arrhythmias requiring medication; left ventricular ejection fraction (LVEF) \\\u003C 50%.\n8. Active or uncontrolled severe infection (≥ CTCAE v5.0 Grade 2 infection).\n9. Known HIV infection. Known clinically significant liver disease, including viral hepatitis \\[known hepatitis B virus (HBV) carriers must be excluded if they have active HBV infection, i.e., HBV DNA positive (\\>1×10⁴ copies\u002FmL or \\>2000 IU\u002FmL); known hepatitis C virus (HCV) infection with HCV RNA positive (\\>1×10³ copies\u002FmL)\\].\n10. Any other disease, clinically significant metabolic abnormality, physical examination finding, or laboratory abnormality that, in the investigator's judgment, reasonably suggests the presence of a disease or condition that contraindicates the use of the investigational drug (e.g., a condition associated with seizures requiring treatment), would affect the interpretation of study results, or would place the patient at high risk.\n11. Patients deemed by the investigator to be unsuitable for participation in this study.",{"count":539,"type":22},93,[158],"Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor worldwide, with particularly high incidence in East Asian regions such as China, and is associated with poor patient prognosis. In recent years, immune checkpoint inhibitors (e.g., anti-PD-1\u002FPD-L1 antibodies) combined with chemotherapy have become the standard first-line treatment for advanced ESCC. Multiple randomized controlled trials have confirmed that this combination significantly improves patient survival compared to chemotherapy alone. However, a subset of patients still exhibit poor response or develop resistance to the immunotherapy-chemotherapy regimen, necessitating the exploration of novel combination strategies to further enhance efficacy.\n\nThe epidermal growth factor receptor (EGFR) is frequently overexpressed in ESCC and is associated with tumor proliferation, metastasis, and poor prognosis, making it an important therapeutic target. Antibody-drug conjugates (ADCs) targeting EGFR achieve precise tumor killing by conjugating an anti-EGFR antibody to a potent cytotoxic payload. Preclinical studies have demonstrated significant antitumor activity of EGFR ADCs in ESCC models. Mechanistically, anti-EGFR therapy and immune checkpoint inhibitor therapy may exert synergistic effects through several avenues: enhancing tumor antigen presentation, remodeling the tumor microenvironment, and modulating PD-L1 expression. Therefore, this triple combination strategy holds promise for overcoming the limitations of monotherapies and providing a new treatment option for patients with ESCC.",[543,165,33,544,545,546],"ESCC","Becotatug Vedotin","EGFR ADC","PD-1 Inhibitor","2026-04-13",{"date":549,"type":48},"2026-04-15",{"date":551,"type":22},"2026-04-01",{"date":553,"type":22},"2029-12-31",{"name":555,"class":55},"Tianjin Medical University Cancer Institute and Hospital",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":67,"phases":566,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":277},"100232534","hypoglossal-acupuncture-for-dysgeusia-in-patients-undergoing-chemotherapy-100232534","NCT02304913","Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy","Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial","OralAcu","Inclusion Criteria:\n\n* Initial treatment with platinum-containing or taxane-based CTX (regardless of the the length of the CTX cycle)\n* Senological, gynecological or internistic tumors\n* Phantogeusia (on average ≥4 NRS)\n* Willingness to participate in the study and written informed consent\n\nExclusion Criteria:\n\n* Severe stomatitis\n* Dysgeusia before the CTX based on neurological diseases, diabetes, or the ingestion of drugs with taste disorders as side effects\n* Leucopenia\u002Fneutropenia\n* Intake of anticoagulants\n* Smoking\n* Severe physical or mental comorbidity (due to which the patient is unable to participate in the study)\n* Participation in other CAM treatments within the integrative oncology care\n* Participation in other studies on the effectiveness of interventions for oral complications",{"count":565,"type":22},75,[69],"This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of dysgeusia in cancer patients undergoing chemotherapy.",[569,570,571,33,72],"Acupuncture","Taste Disorders","Dysgeusia","2026-04-09",{"date":574,"type":48},"2026-04-14",{"date":576,"type":48},"2015-01-01",{"date":381,"type":22},{"name":579,"class":55},"Universität Duisburg-Essen",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":63,"minAge":587,"maxAge":367,"enrollmentInfo":588,"targetDuration":4,"studyType":67,"phases":590,"briefSummary":592,"conditions":593,"keywords":596,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":117},"100510547","phase-1-ramucirumab-cyramza-nal-iri-onivyde-and-trifluridinetipiracil-lonsurf-in-second-line-metastatic-gastric-cancer--100510547","NCT05927857","Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine\u002FTipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","A Phase Ib\u002FII Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine\u002FTipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).","Inclusion Criteria:\n\n1. histologically or cytologically confirmed metastatic gastric adenocarcinoma\n2. patients have received only first line of systemic therapy, including recurrence during adjuvant therapy or within 6 months after the completion of adjuvant treatment.\n3. ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1\n4. patients with HER2\u002Fneu-positive tumor must be exposure to Herceptin treatment\n5. at least one measurable disease according to the RECIST version 1.1;\n6. patients are aged 20 to 80 years;\n7. patients have a life expectancy ≥ 3 months;\n8. patients have adequate renal function with defined as serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or Ccr ≥ 40 mL\u002Fmin;\n9. patients with adequate hepatic function as defined by a total bilirubin ≤1.5 times the ULN, and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times the ULN or 5 times the ULN in the setting of liver metastases.\n10. patients have adequate bone marrow function, defined as an absolute neutrophil count ≥ 1500\u002Fmm3, hemoglobin ≥9 g\u002FdL, and platelet count ≥ 100,000\u002Fmm3 (transfusion or G-CSF support before enrollment is allowed)\n11. patients have International Normalized Ratio (INR) ≤1.5 and a partial thromboplastin time (PTT) (PTT\u002FaPTT) \\\u003C 1.5 x ULN;\n12. patients' urinary protein is ≤1+ on dipstick or routine urinalysis or a 24-hour urine collection for protein must demonstrate \\\u003C1000 mg of protein if urine dipstick or routine analysis is ≥ 2+;\n13. patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study;\n14. female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy;\n15. the ability to understand and willingness and to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. patient can't take oral drugs;\n2. known hypersensitivity to irinotecan, fluoropyrimidine, or ramucirumab;\n3. receipt of surgery within the past 4 weeks before study enrollment;\n4. ≥ grade 2 diarrhea and ascites\n5. concurrent severe infection with intravenous systemic antibiotics treatment;\n6. patients have experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy;\n7. patients have a prior history of GI perforation\u002Ffistula (within 6 months of first dose of protocol therapy) or risk factors for perforation;\n8. patients have:\n\n   * cirrhosis at a level of Child-Pugh B (or worse) or\n   * cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis;\n9. patients have a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy;\n10. patients have undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery\u002Fsubcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy. Patients have elective or planned major surgery to be performed during the course of the clinical trial;\n11. patients have uncontrolled or poorly-controlled hypertension (\\>160 mmHg systolic or \\> 100 mmHg diastolic for \\>4 weeks) despite standard medical management;\n12. patients have experienced any grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy;\n13. patients have a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \"significant\") during the 3 months prior to first dose of protocol therapy;\n14. patients are receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg\u002Fday) is permitted;\n15. previously received prior nal-IRI (ONIVYDE®) or TAS-102 (LONSURF®) or ramucirumab therapy\n16. another previous malignancy diagnosed within the past 5 years except for non melanoma skin cancer or stage I cervical cancer;\n17. pregnant or breast feeding women.","20 Years",{"count":589,"type":22},45,[591,158],"PHASE1","Primary Objectives\n\n* In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®)\n* In phase II cohort, to evaluate disease objective response rate (ORR) of Ramucirumab (Cyramza®), nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) Secondary Objectives\n* To evaluate disease control rate (DCR)\n* To evaluate progression-free survival (PFS)\n* To evaluate overall survival (OS)\n* To assess the safety profile\n* To study the blood biomarkers",[594,595,33],"Metastatic Gastric Adenocarcinoma","Second Line",[597,598,599],"nal-IRI (ONIVYDE)","TAS-102 (LONSURF)","Ramucirumab (Cyramza)","2026-04-06",{"date":572,"type":48},{"date":603,"type":48},"2024-04-01",{"date":216,"type":22},{"name":606,"class":55},"National Health Research Institutes, Taiwan",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":63,"minAge":19,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":616,"conditions":617,"keywords":622,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":642},"100578269","home-monitoring-of-complete-blood-count-performed-by-patients---a-pilot-study-on-the-implementation-process-in-south-baltic-countries-100578269","NCT06809101","Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.","AMBeR eBlood","Inclusion Criteria:\n\n* legally competent patients\n* aged 18 or older\n* diagnosed with cancer (ICD-10: C00\\* - C97\\*)\n* enrolled at the Department of Oncology\u002FHematology for outpatients\n* participants who are willing and able to give informed consent for participation in the study\n* participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion\n\nExclusion Criteria:\n\n* inability to give informed consent due to mental capacity or language barrier\n* patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result\n* known bleeding disorder\n* bad circulation preventing the patient from getting enough blood drops to perform the test",{"count":615,"type":22},265,"Introduction:\n\nThe number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment. In case of poor blood results, the chemotherapy session must be omitted. For patients living far from the center, this means unnecessary travel with involvement of helpers, additional costs, increased potential of hospital acquired infections, and frustration associated with missed opportunity for treatment.\n\nAims:\n\nThe primary aim of this study is to gain knowledge about successful implementation of remote, home monitoring of complete blood count to cancer patients during and after systemic treatment for cancer. The secondary aim of the AMBeR collective study protocol is to pilot new technology, gain more context around future investigations and verify costs and changes in patient treatment pathways.\n\nMethodology:\n\nThe investigators will test implementation of home blood monitoring in three South Baltic Countries (DK, PL, GER). Each site will participate in the implementation study with study group á n=33 (total n=165) and control group n=20 (total n=100). The duration of the study is planned for 4 cycles of chemotherapy for each patient and a 3-month follow up period. The first cycle of learning and training at the Outpatient Daily Clinic, then the remaining 3 cycles of blood monitoring at home. The average cycle length is 21-30 days, number of measurements will be determined individually depending on the diagnosis. At a baseline, after 4 cycles of chemotherapy (12-16 weeks) and after a 3-month follow-up period, parallel studies will be carried out in both the study and control groups, using mixed methods the investigators will assess outcomes of reach, effectiveness, adoption, implementation and maintenance (RE-AIM).\n\nExpected benefits:\n\nImplementation of the AMBeR study should reduce the amount of unnecessary and nontherapeutic hospital visits and improve manageability and independence of the patients. The investigators believe that the decrease in the number of hospital visits will diminish the risk of infection for vulnerable individuals, as well as save costs for patients and hospitals. These factors will also translate into better logistics of chemotherapy units, decreased carbon-dioxide trail, and improved quality of life and patient empowerment.",[72,618,33,619,620,621],"Cancer-related Problem\u002FCondition","Chemotherapy-induced Neutropenia","Chemotherapy Induced Anaemia","Chemotherapy Induced Thrombocytopenia",[623,624,625,626,627,628,629,630,631,632],"home blood monitoring","complete blood count","cancer","chemotherapy","implementation","research","e-health","oncology","home-based","feasibility","2026-02-26",{"date":635,"type":48},"2026-02-27",{"date":637,"type":48},"2025-03-17",{"date":639,"type":22},"2027-03-31",{"name":641,"class":55},"Pomeranian Medical University Szczecin",5,{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":63,"minAge":4,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":653,"conditions":654,"keywords":660,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":117},"100623759","cervical-cancer-oligo-states-recurrence-metastasis-multicentre-outcomes-study-100623759","NCT07400809","Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retro-COSMOS","Inclusion Criteria:\n\n1. Cervical cancer with (induced) oligo-metastatic and\u002For oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials\u002Fstudies.\n2. Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.\n3. Patients treated with radical doses at the time of first diagnosis of oligo-metastasis\u002Foligo-recurrence and present with further oligo-progression.\n4. Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.\n\nExclusion Criteria:\n\n1. Gynaecological cancer other than cervical cancer.\n2. Persistent Poly-metastatic disease post systemic treatment\n3. Receiving investigational new drugs at the time of relapse as part of other ongoing trials.\n4. No clinical follow up after treatment",{"count":652,"type":22},350,"Systemic chemotherapy with or without palliative radiation represents the current standard of care in patients with recurrent or metastatic cervix cancer. In addition, pelvic radiotherapy including brachytherapy is also recommended. There is no consensus on the treatment of metastatic site in patients with oligo-metastatic or oligo-recurrent cervix cancer. Also, it is not clear if addition of local treatment to systemic chemotherapy benefits all patients with metastatic disease or a select few with limited systemic disease burden. It's presently unclear which patients derive maximum benefit with integration of radiation at both primary and metastatic site, who develop infield recurrence if performing salvage surgery, locally directed treatments or re-irradiation in addition to systemic chemotherapy improves overall outcomes. The heterogeneity in clinical practice provides an important opportunity to develop a framework for data collection and future studies within such subgroup of patients. In this retrospective study, we aim to determine overall survival, Infield progression free survival, overall progression free survival, dose response relationship of nodal and visceral progressions, and within setting of re-irradiation (infield progressions), severe adverse events and toxicity, risk groups identification, a nomogram which correlates risk groups with expected outcomes, and framework for tissue collection for translational research Investigators will record the parameters in a predesigned proforma without including personal identifiers.",[33,655,34,656,657,658,659],"Treatment Compliance","Cervix Cancer","Surgery","Recurrent","Metastasis",[661,662],"Recurrent and Metastatic Cervix Cancer","Oligo States","2026-02-12",{"date":665,"type":48},"2026-02-17",{"date":667,"type":48},"2023-08-23",{"date":669,"type":22},"2027-06-14",{"name":671,"class":672},"Tata Memorial Hospital","OTHER_GOV"]